{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:03:59Z","timestamp":1785168239014,"version":"3.55.0"},"reference-count":49,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2015,3,5]]},"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Little clinical data are available regarding the optimal treatment of patients who harbour adefovir-resistant HBV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>In this multicentre trial, patients who had adefovir-resistant HBV with serum HBV DNA levels &gt;60\u2005IU\/mL were randomised to receive tenofovir disoproxil fumarate (TDF, 300\u2005mg\/day) monotherapy (n=50) or TDF and entecavir (ETV, 1\u2005mg\/day) combination therapy (TDF\/ETV, n=52) for 48\u2005weeks. All who completed 48\u2005weeks in either group received TDF monotherapy for 48 additional weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline characteristics were comparable between groups, including HBV DNA levels (median, 3.38 log<jats:sub>10<\/jats:sub> IU\/mL). All patients had adefovir-resistant HBV mutations; rtA181V\/T and\/or rtN236T. The proportion of patients with HBV DNA &lt;15\u2005IU\/mL was not significantly different between the TDF-TDF and TDF\/ETV-TDF groups at weeks 48 (62% vs 63.5%; p=0.88) and 96 (64% vs 63.5%; p=0.96). The mean change in HBV DNA levels from baseline was not significantly different between groups at week 48 (\u22123.03 log<jats:sub>10<\/jats:sub> IU\/mL vs \u22123.31 log<jats:sub>10<\/jats:sub> IU\/mL; p=0.38). Virological breakthrough occurred in one patient on TDF-TDF and two patients on TDF\/ETV-TDF over 96\u2005weeks; all were attributed to poor drug adherence. At week 96, five and two patients in the TDF-TDF and TDF\/ETV-TDF groups, respectively, retained some of their baseline resistance mutations (p=0.44). None developed additional resistance mutations. Safety profiles were comparable in the two groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with adefovir-resistant HBV and multiple-drug failure, TDF monotherapy provided a virological response comparable to that of TDF and ETV combination therapy, and was safe up to 96\u2005weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>NCT01639066.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2014-308435","type":"journal-article","created":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T22:42:14Z","timestamp":1427150534000},"page":"1042-1051","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":77,"title":["Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial"],"prefix":"10.1136","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct01639066","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Young-Suk","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Chul","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Soo","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"An","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Chu","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung Sang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,3,23]]},"reference":[{"key":"2025090800064228000_65.6.1042.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"2025090800064228000_65.6.1042.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"2025090800064228000_65.6.1042.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033364"},{"key":"2025090800064228000_65.6.1042.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.09.062"},{"key":"2025090800064228000_65.6.1042.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.026"},{"key":"2025090800064228000_65.6.1042.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20760"},{"key":"2025090800064228000_65.6.1042.7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease","volume":"12","author":"Yuen","year":"2007","journal-title":"Antivir Ther"},{"key":"2025090800064228000_65.6.1042.8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26180"},{"key":"2025090800064228000_65.6.1042.9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26301"},{"key":"2025090800064228000_65.6.1042.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.033"},{"key":"2025090800064228000_65.6.1042.11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.048"},{"key":"2025090800064228000_65.6.1042.12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"2025090800064228000_65.6.1042.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26686"},{"key":"2025090800064228000_65.6.1042.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"2025090800064228000_65.6.1042.15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"2025090800064228000_65.6.1042.16","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2012.18.2.109"},{"key":"2025090800064228000_65.6.1042.17","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-012-9365-4"},{"key":"2025090800064228000_65.6.1042.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.053"},{"key":"2025090800064228000_65.6.1042.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.024"},{"key":"2025090800064228000_65.6.1042.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.028"},{"key":"2025090800064228000_65.6.1042.21","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.223206"},{"key":"2025090800064228000_65.6.1042.22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308353"},{"key":"2025090800064228000_65.6.1042.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60012-9"},{"key":"2025090800064228000_65.6.1042.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70314-0"},{"key":"2025090800064228000_65.6.1042.25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi","year":"2007","journal-title":"Antivir Ther"},{"key":"2025090800064228000_65.6.1042.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.027"},{"key":"2025090800064228000_65.6.1042.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"key":"2025090800064228000_65.6.1042.28","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1702"},{"key":"2025090800064228000_65.6.1042.29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20723"},{"key":"2025090800064228000_65.6.1042.30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21290"},{"key":"2025090800064228000_65.6.1042.31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.08.013"},{"key":"2025090800064228000_65.6.1042.32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22295"},{"key":"2025090800064228000_65.6.1042.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.09.022"},{"key":"2025090800064228000_65.6.1042.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00939-9"},{"key":"2025090800064228000_65.6.1042.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.020"},{"key":"2025090800064228000_65.6.1042.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23145"},{"key":"2025090800064228000_65.6.1042.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802878"},{"key":"2025090800064228000_65.6.1042.38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23246"},{"key":"2025090800064228000_65.6.1042.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.018"},{"key":"2025090800064228000_65.6.1042.40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00338-12"},{"key":"2025090800064228000_65.6.1042.41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00587-13"},{"key":"2025090800064228000_65.6.1042.42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3851\/IMP1914","article-title":"Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside\/nucleotide analogues","volume":"17","author":"Lim","year":"2012","journal-title":"Antivir Ther"},{"key":"2025090800064228000_65.6.1042.43","first-page":"314A","article-title":"The safety and efficacy of entecavir and tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure: week 96 results of the ENTEBE study","volume":"60","author":"Zoulim","year":"2014","journal-title":"Hepatology"},{"key":"2025090800064228000_65.6.1042.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051285"},{"key":"2025090800064228000_65.6.1042.45","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.037"},{"key":"2025090800064228000_65.6.1042.46","doi-asserted-by":"crossref","unstructured":"Mallet V , Schwarzinger M , Vallet-Pichard A , et al . Effect of Nucleoside and Nucleotide Analogues on Renal Function in Patients With Chronic Hepatitis B Virus Monoinfection. Clin Gastroenterol Hepatol Published Online First: 21 Nov 2014. doi:10.1016\/j.cgh.2014.11.021 doi:10.1016\/j.cgh.2014.11.021","DOI":"10.1016\/j.cgh.2014.11.021"},{"key":"2025090800064228000_65.6.1042.47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.12229","article-title":"Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China","volume":"22","author":"Qi","year":"2015","journal-title":"J Viral Hepat"},{"key":"2025090800064228000_65.6.1042.48","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(14)61221-6","article-title":"Long-term treatment with tenofovir in treatment-naive or -experienced CHB patients is effective and well tolerated in real-life practice: 3 years results of the VIREAL study","volume":"60","author":"Pageaux","year":"2014","journal-title":"J Hepatol"},{"key":"2025090800064228000_65.6.1042.49","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.063"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2014-308435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:06:50Z","timestamp":1757315210000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2014-308435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,23]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,10]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1136\/gutjnl-2014-308435"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2014-308435","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,23]]}}}